JCS/JHFS 2018 Guideline on the Diagnosis and Treatment of Cardiomyopathies
Hiroaki Kitaoka, Hiroyuki Tsutsui, Toru Kubo, Tomomi Ide, Taishiro Chikamori, Keiichi Fukuda, Noboru Fujino, Taiki Higo, Mitsuaki Isobe, Chizuko Kamiya, Seiya Kato, Yasuki Kihara, Koichiro Kinugawa, Shintaro Kinugawa, Shigetoyo Kogaki, Issei Komuro, Nobuhisa Hagiwara, Minoru Ōno, Yuichiro Maekawa, Shigeru Makita, Yoshiro Matsui, Shouji Matsushima, Yasushi Sakata, Yoshiki Sawa, Wataru Shimizu, Kunihiko Teraoka, Miyuki Tsuchihashi‐Makaya, Hatsue Ishibashi‐Ueda, Masafumi Watanabe, Michihiro Yoshimura, Arata Fukusima, Satoshi Hida, Shungo Hikoso, Teruhiko Imamura, Hiroko Ishida, Makoto Kawai, Toshiro Kitagawa, Takashi Kohno, Satoshi Kurisu, Yoji Nagata, Makiko Nakamura, Hiroyuki Morita, Hitoshi Takano, Tsuyoshi Shiga, Yasuyoshi Takei, Shinsuke Yuasa, Teppei Yamamoto, Tetsu Watanabe, Takashi Akasaka, Yoshinori Doi, Takeshi Kimura, Masafumi Kitakaze, Masami Kosuge, Morimasa Takayama, Hitonobu Tomoike, on behalf of the Japanese Circulation Society Joint Working Group
Abstract
SA-I, SA-II *The morphofunctional phenotype description (M) may contain more information using standard abbreviations, such as AVB, atrioventricular block; WPW, Wolff-Parkinson-White syndrome; LQT, prolongation of the QT interval; AF, atrial fibrillation; R, low electrocardiogram voltages; PR, short PR interval. Organ (O) involvement in addition to the H subscript (for heart) should be expanded for the involvement of M